NCT01526356.

Methods	Multicentre prospective, randomised, double‐blind, placebo‐controlled study.
Participants	177 participants diagnosed with TSC and visible facial angiofibromas.
Interventions	Participants were randomised into either: 1. topical placebo cream; OR 2. topical 0.1% rapamycin cream; OR 3. topical 1% rapamycin cream. Study cream is applied nightly to the affected areas on the face.
Outcomes	Primary outcome: reduction in lesion size and appearance. Photographic, visual, and measurable reduction in the size and severity of the lesions. Secondary outcomes: systemic uptake of topically applied rapamycin; dermatologic sensitivity at the site of application.
Notes	Sponsored by The University of Texas Health Science Center, Houston.

IQ: intelligence quotient
 TSC: tuberous sclerosis complex